About the paper
This paper focuses on the role of sterility testing in the release of aseptically manufactured medicinal products and its integration into a Contamination Control Strategy (CCS). It outlines how risk assessment can be used as a scientifically sound and practical approach to identify critical control points and ensure compliance with Annex 1 of the EU-GMP-guidelines.
Why the topic matters
Sterility testing is a critical step in ensuring the safety and efficacy of aseptically produced medicinal products before they are released to the market. Regulatory requirements demand that this testing be fully integrated into a comprehensive contamination control strategy. A structured risk assessment approach helps identify and control potential contamination risks, ensuring both compliance and product safety while enabling continuous process improvement.